The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease
Open accessAbstract
Purpose: To perform the first meta-analysis of the performance of the genomic classifier test, Decipher, in men with prostate cancer postprostatectomy. Methods: MEDLINE, EMBASE, and the Decipher genomic resource information database were searched for published reports between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher test. Multivariable Cox proportional hazards models fit to individual patient data were performed; meta-analyses were conducted by pooling the study-specific hazard ratios (HRs) using random-effects modeling. Extent of heterogeneity between studies was determined with the I 2 test. Results: Five studies (975 total patients, and 855 patients with individual patient-level data) were eligible for analysis, with a median follow-up of 8 years. Of the total cohort, 60.9%, 22.6%, and 16.5% of patients were classified by Decipher as low, intermediate, and high risk, respectively. The 10-year cumulative incidence metastases rates were 5.5%, 15.0%, and 26.7% ( P < .001), respectively, for the three risk classifications. Pooling the study-specific Decipher HRs across the five studies resulted in an HR of 1.52 (95% CI, 1.39 to 1.67; I 2 = 0%) per 0.1 unit. In multivariable analysis of individual patient data, adjusting for clinicopathologic variables, Decipher remained a statistically significant predictor of metastasis (HR, 1.30; 95% CI, 1.14 to 1.47; P < .001) per 0.1 unit. The C-index for 10-year distant metastasis of the clinical model alone was 0.76; this increased to 0.81 with inclusion of Decipher. Conclusion: The genomic classifier test, Decipher, can independently improve prognostication of patients postprostatectomy, as well as within nearly all clinicopathologic, demographic, and treatment subgroups. Future study of how to best incorporate genomic testing in clinical decision-making and subsequent treatment recommendations is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290 · cited 1×
“Cumulative incidence curves were constructed using Fine-Gray competing risks analysis to estimate the risk of metastasis over time, with deaths from other causes as a competing risk.(18) Time-dependent C indices were constructed using the approach described by Heagerty et al.”
MethodModeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., & Tierney, J. F. (2015) · JAMA · doi:10.1001/jama.2015.3656 · Cited by 2,134
Racial/ethnic disparities in genomic sequencing
Spratt, D. E., Chan, T., Waldron, L., Speers, C., Feng, F. Y., Ogunwobi, O. O., & Osborne, J. R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1854 · Cited by 375
Self-citation
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Self-citationArtificial intelligence for clinical oncology
Kann, B. H., Hosny, A., & Aerts, H. J. W. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.002 · Cited by 370
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303974 · Cited by 319
Self-citationGenomic Markers in Prostate Cancer Decision Making
Cucchiara, V., Cooperberg, M. R., Dall’Era, M., Lin, D. W., Montorsi, F., Schalken, J. A., & Evans, C. P. (2018) · European Urology · doi:10.1016/j.eururo.2017.10.036 · Cited by 269
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Duffy, M. J. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0693 · Cited by 267
Metadata
- Authors
- Spratt, D. E., Yousefi, K., Deheshi, S., Ross, A. E., Den, R. B., Schaeffer, E. M., Trock, B. J., Zhang, J., Glass, A. G., Dicker, A. P., Abdollah, F., Zhao, S. G., Lam, L. L. C., du Plessis, M., Choeurng, V., Haddad, Z., Buerki, C., Davicioni, E., Weinmann, S., Freedland, S. J., Klein, E. A., Karnes, R. J., & Feng, F. Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-06-20
- Volume
- 35
- Issue
- 18
- Pages
- 1991-1998
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2601335591
- Cited by
- 247
- References
- 4
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.